|Bid||221.47 x 1000|
|Ask||223.92 x 800|
|Day's range||221.75 - 229.04|
|52-week range||221.72 - 468.55|
|Beta (5Y monthly)||0.40|
|PE ratio (TTM)||21.92|
|Earnings date||01 Feb 2022 - 07 Feb 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||345.39|
If you're enrolled in Medicare Part B, your premiums will increase quite a bit next year. The Centers for Medicare and Medicaid Services (CMS) singled out one drug as a key reason behind the coming hike: Biogen's (NASDAQ: BIIB) Alzheimer's disease drug Aduhelm. In this Motley Fool Live video recorded on Nov. 16, Fool contributors Keith Speights and Brian Orelli discuss whether beneficiaries should really blame Biogen for their higher Medicare Part B premiums.
Sage Therapeutics (SAGE) and partner Biogen (BIIB) announce positive data from a cohort of an ongoing phase III study, currently evaluating their investigational major depressive disorder drug zuranolone.
With its stock down 32% over the past three months, it is easy to disregard Biogen (NASDAQ:BIIB). However, stock prices...